Celltrion wins another Brazilian tender for biosimilars
South Korea’s Celltrion Healthcare (Kosdaq: 068270) today announced that it has signed a contract to supply its two anticancer therapeutics – Herzuma (trastuzumab) and Truxima (rituximab) to the Brazilian market. The company won the order in an open bidding held by the Ministry of Health of Federal Government of Brazil, marking two consecutive years of winning the bid.
Under the contract, the company will supply Herzuma, a biosimilar of Roche’s (ROG: SIX) blockbuster cancer drug Herceptin, to the public market, which accounts for approximately 80% of Brazil's trastuzumab market. The company has won a total of eight state bids for Truxima, a biosimilar of Roche’s Rituxan/MabThera, this year, including a bid in Sao Paulo, which is the largest of Brazil's state bids.
Huge demand for biosimilars in Latin America
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze